Pancreatic cancer is hard to detect early and notoriously resistant to treatment, making it the deadliest type of major cancer. Rafael Pharmaceuticals, a small drug maker backed by a telecom billionaire, hopes to deliver better news for patients and investors with the readout of a large clinical trial within the next two months.
It’s an inordinately risky challenge for Rafael, but with a giant payoff if successful. Here are six things to know about the company and its drug, devimistat, before Phase 3 pancreatic cancer study results are announced.
Create a display name to comment
This name will appear with your comment